ANEURYSMS of the thoracic aorta may be of diverse etiology. Atherosclerosis ... that time a heart murmur was first noted. In spite of treatment with digitalis, diuretics and salt restriction ...

Atherosclerotic plaques are a feature of abdominal aortic aneurysms (AAAs). Atherosclerosis and AAA ... of AAA and their implications for treatment. There is insufficient evidence to confirm ...

The factors underlying accelerated atherosclerosis in diabetes extend ... For each mouse, the aorta was perfused gently with PBS in a retrograde manner and the heart was then removed and stored ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Rates of treatment emergent adverse events ... In preclinical models of atherosclerosis, CD47 receptor occupancy of 6-26% correlated with meaningful reductions in aortic plaque burden relative to ...

These findings may impact healthcare practices and the establishment of standardised treatment protocols, thus prompting further comprehensive investigations into the pathophysiology. Chronic ...

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 ...

We are beyond honored to welcome Dr. Ridker, a luminary in the field who has helped to fundamentally transform our understanding of cardiovascular disease,” said Sandeep Kulkarni, MD, Co-Founder and ...

New York, USA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Myocardial Infarction Clinical Trial Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...

Despite many reports in the literature, recently published guidelines point out the fact that concern remains regarding the optimal strategies for diagnosis and treatment ... that aortic stenosis ...

According to GlobalData, Phase I drugs for Atherosclerosis have a 64 ... CTX-320 is under development for the treatment of atherosclerotic cardiovascular disease (ASCVD) with elevated Lp(a) and aortic ...